These data suggest that the combinatorial treatment of a chemotherapeutic drug, doxorubicin at a low dose and the potent EGFR inhibitor/compound 1e effectively regressed the tumor growth by inhibiting the tumorigenic potential of the breast CSCs. Here, EGFR is linked to neoplasm.